|
|
|
|
|
Deniz Can Guven, Taha Koray Sahin, Alessandro Rizzo, Angela Dalia Ricci, Sercan Aksoy and Kazim Sahin
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and reshaped medical oncology practice over the past decade. However, despite unprecedented and durable clinical responses, most patients eventually fail to respond to ICI therapy due...
ver más
|
|
|
|
|
|
|
|
|
|
|
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro and Isao Sakaida
Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a tre...
ver más
|
|
|
|
|
|
|
|
|
|
|
OPhir Nave and Moriah Sigron
Skin cancer treatment is a combination of BRAF and MEK kinase inhibitors administered as tablets, along with immunotherapy treatment (treatment into the vein) with a group of drugs that inhibit the activity of the immune barrier proteins PD-1 and PDL1. H...
ver más
|
|
|
|
|
|